Last updated 27 days ago

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

300 patients around the world
Available in Chile, United States
Sanofi
300Patients around the world
This study is for people with
Bronchiectasis
Requirements for the patient
To 85 Years
All Gender
Medical requirements
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy